1.28
price up icon3.23%   0.04
after-market Dopo l'orario di chiusura: 1.27 -0.01 -0.78%
loading
Precedente Chiudi:
$1.24
Aprire:
$1.22
Volume 24 ore:
10,519
Relative Volume:
0.03
Capitalizzazione di mercato:
$34.46M
Reddito:
$9.06M
Utile/perdita netta:
$-50.39M
Rapporto P/E:
-0.6667
EPS:
-1.92
Flusso di cassa netto:
$5.89M
1 W Prestazione:
-2.29%
1M Prestazione:
+0.79%
6M Prestazione:
-32.63%
1 anno Prestazione:
-58.71%
Intervallo 1D:
Value
$1.22
$1.28
Intervallo di 1 settimana:
Value
$1.20
$1.33
Portata 52W:
Value
$0.8502
$3.20

Lava Therapeutics Nv Stock (LVTX) Company Profile

Name
Nome
Lava Therapeutics Nv
Name
Telefono
31 6 3000 3035
Name
Indirizzo
YALELAAN 62, UTRECHT
Name
Dipendente
34
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-28
Name
Ultimi documenti SEC
Name
LVTX's Discussions on Twitter

Confronta LVTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LVTX
Lava Therapeutics Nv
1.28 34.46M 9.06M -50.39M 5.89M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-12 Downgrade Leerink Partners Outperform → Market Perform
2024-12-11 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2022-10-25 Iniziato H.C. Wainwright Buy
2021-04-19 Iniziato JP Morgan Overweight
2021-04-19 Iniziato Jefferies Buy
2021-04-19 Iniziato SVB Leerink Outperform
Mostra tutto

Lava Therapeutics Nv Borsa (LVTX) Ultime notizie

pulisher
Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Lava Therapeutics Granted Full Waiver For RVO Payment Obligation - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire

Apr 16, 2025
pulisher
Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt - Stock Titan

Apr 16, 2025
pulisher
Apr 06, 2025

Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st

Apr 06, 2025
pulisher
Apr 01, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com

Mar 31, 2025
pulisher
Mar 28, 2025

Lava Therapeutics Reports 2024 Financial Results - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics NV SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics Slashes Workforce 30% While Securing $12M in Big Pharma Milestone Payments - Stock Titan

Mar 28, 2025
pulisher
Mar 12, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com

Mar 12, 2025
pulisher
Feb 28, 2025

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga

Feb 28, 2025
pulisher
Feb 27, 2025

This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

Feb 27, 2025
pulisher
Feb 25, 2025

LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

LAVA Announces Evaluation of Strategic Options - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan

Feb 25, 2025
pulisher
Feb 13, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia

Feb 13, 2025
pulisher
Feb 12, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 06, 2025

LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World

Feb 06, 2025
pulisher
Jan 27, 2025

RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR

Jan 27, 2025
pulisher
Jan 10, 2025

LAVA Therapeutics begins trial for cancer treatment - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire

Jan 10, 2025
pulisher
Jan 10, 2025

LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan

Jan 10, 2025
pulisher
Jan 09, 2025

LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register

Jan 09, 2025
pulisher
Jan 04, 2025

LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World

Jan 04, 2025
pulisher
Dec 26, 2024

LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com

Dec 26, 2024
pulisher
Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com

Dec 20, 2024
pulisher
Dec 18, 2024

LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com

Dec 18, 2024

Lava Therapeutics Nv Azioni (LVTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Capitalizzazione:     |  Volume (24 ore):